Miller V - Search Results

1

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. Aghajanian C, et al. Among authors: miller v. Clin Cancer Res. 2002 Aug;8(8):2505-11. Clin Cancer Res. 2002. PMID: 12171876 Clinical Trial.

2

A phase I trial of perillyl alcohol in patients with advanced solid tumors.

Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG. Azzoli CG, et al. Cancer Chemother Pharmacol. 2003 Jun;51(6):493-8. doi: 10.1007/s00280-003-0599-7. Epub 2003 Apr 15. Cancer Chemother Pharmacol. 2003. PMID: 12695855 Clinical Trial.

3

Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550).

Soignet SL, Miller VA, Pfister DG, Bienvenu BJ, Ho R, Parker BA, Amyotte SA, Cato A 3rd, Warrell RP Jr. Soignet SL, et al. Among authors: miller va. Clin Cancer Res. 2000 May;6(5):1731-5. Clin Cancer Res. 2000. PMID: 10815891 Clinical Trial.

4

Using patients as their own controls for cost evaluation of phase I clinical trials.

Sherman EJ, Rubin DM, Venkatraman E, Schwartz GK, Miller VA, Radzyner MH, Ruchlin HS, Spriggs D, Pfister DG. Sherman EJ, et al. J Clin Oncol. 2004 Apr 1;22(7):1308-14. doi: 10.1200/JCO.2004.06.118. J Clin Oncol. 2004. PMID: 15051779 Clinical Trial.

5

Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.

Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O'Reilly EM, Muller RJ, Kris MG. Azzoli CG, et al. Am J Clin Oncol. 2003 Jun;26(3):247-51. doi: 10.1097/01.COC.0000017782.24458.DD. Am J Clin Oncol. 2003. PMID: 12796593 Review.

6

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.

Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM. Krug LM, et al. Among authors: miller va. Clin Cancer Res. 2000 Sep;6(9):3493-8. Clin Cancer Res. 2000. PMID: 10999734 Clinical Trial.

7

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM. She Y, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3773-8. Clin Cancer Res. 2003. PMID: 14506170

8

Pharmacokinetics and toxicity of weekly docetaxel in older patients.

Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, Caravelli J, Yeung H, Kris MG, Gomez J, Miller VA, D'Andrea G, Scher HI, Norton L, Hudis C. Hurria A, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6100-5. doi: 10.1158/1078-0432.CCR-06-0200. Clin Cancer Res. 2006. PMID: 17062686

9

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM. Azzoli CG, et al. Clin Cancer Res. 2007 May 1;13(9):2692-8. doi: 10.1158/1078-0432.CCR-06-1754. Clin Cancer Res. 2007. PMID: 17473201 Clinical Trial.

10

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ. Janjigian YY, et al. Clin Cancer Res. 2011 Apr 15;17(8):2521-7. doi: 10.1158/1078-0432.CCR-10-2662. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248303 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,957 results

Search Page

Filters